Company intelligence / Profile preview

Phrixus Pharmaceuticals, Inc.

Ann Arbor, Michigan, United Statespmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Employees: ~3
Development stage: Phase 2

Overview

Phrixus Pharmaceuticals developed Carmeseal-MD (Poloxamer 188 NF or P-188 NF) for treating Duchenne muscular dystrophy. The company conducted a Phase 2 clinical trial of P-188 NF in non-ambulatory patients with DMD. The trial was designed as a single-center, open-label study to evaluate the safety, tolerability, and efficacy of daily subcutaneous dosing in non-ambulatory boys with DMD. The trial was terminated according to clinical trial records.

Therapeutic areas: Rare DiseasesCardiovascular
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

Carmeseal-MD

Preclinical

Partnerships

Cincinnati Children's HospitalDMD patient organizations

Beyond the preview

Go deeper on Phrixus Pharmaceuticals, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Phrixus Pharmaceuticals, Inc..

Explore the full profile